These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Modifying the conserved C-terminal tyrosine of the peptide hormone PYY3-36 to improve Y2 receptor selectivity. Pedersen SL; Holst B; Vrang N; Jensen KJ J Pept Sci; 2009 Nov; 15(11):753-9. PubMed ID: 19739125 [TBL] [Abstract][Full Text] [Related]
6. Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-36) on food intake. Abbott CR; Small CJ; Kennedy AR; Neary NM; Sajedi A; Ghatei MA; Bloom SR Brain Res; 2005 May; 1043(1-2):139-44. PubMed ID: 15862527 [TBL] [Abstract][Full Text] [Related]
7. Neuropeptide Y (NPY) Y2 receptor-selective agonist inhibits food intake and promotes fat metabolism in mice: combined anorectic effects of Y2 and Y4 receptor-selective agonists. Balasubramaniam A; Joshi R; Su C; Friend LA; James JH Peptides; 2007 Feb; 28(2):235-40. PubMed ID: 17204349 [TBL] [Abstract][Full Text] [Related]
8. NPY2 receptor activation in the dorsal vagal complex increases food intake and attenuates CCK-induced satiation in male rats. Huston NJ; Brenner LA; Taylor ZC; Ritter RC Am J Physiol Regul Integr Comp Physiol; 2019 Apr; 316(4):R406-R416. PubMed ID: 30726118 [TBL] [Abstract][Full Text] [Related]
9. Comparison of independent and combined chronic anti-obese effects of NPY Y2 receptor agonist, PYY(3-36), and NPY Y5 receptor antagonist in diet-induced obese mice. Moriya R; Mashiko S; Ishihara A; Takahashi T; Murai T; Ito J; Mitobe Y; Oda Z; Iwaasa H; Takehiro F; Kanatani A Peptides; 2009 Jul; 30(7):1318-22. PubMed ID: 19394383 [TBL] [Abstract][Full Text] [Related]
10. Neuropeptide Y receptors in primary human brain tumors: overexpression in high-grade tumors. Körner M; Reubi JC J Neuropathol Exp Neurol; 2008 Aug; 67(8):741-9. PubMed ID: 18648328 [TBL] [Abstract][Full Text] [Related]
11. Self-regulation of agonist activity at the Y receptors. Parker SL; Parker MS; Sah R; Balasubramaniam A; Sallee FR Peptides; 2007 Feb; 28(2):203-13. PubMed ID: 17194507 [TBL] [Abstract][Full Text] [Related]
13. Selective role of neuropeptide Y receptor subtype Y2 in the control of gonadotropin secretion in the rat. Pinilla L; Fernández-Fernández R; Roa J; Castellano JM; Tena-Sempere M; Aguilar E Am J Physiol Endocrinol Metab; 2007 Nov; 293(5):E1385-92. PubMed ID: 17785504 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist. Antal-Zimanyi I; Bruce MA; Leboulluec KL; Iben LG; Mattson GK; McGovern RT; Hogan JB; Leahy CL; Flowers SC; Stanley JA; Ortiz AA; Poindexter GS Eur J Pharmacol; 2008 Aug; 590(1-3):224-32. PubMed ID: 18573246 [TBL] [Abstract][Full Text] [Related]
15. Fluorescence- and luminescence-based methods for the determination of affinity and activity of neuropeptide Y2 receptor ligands. Ziemek R; Brennauer A; Schneider E; Cabrele C; Beck-Sickinger AG; Bernhardt G; Buschauer A Eur J Pharmacol; 2006 Dec; 551(1-3):10-8. PubMed ID: 17027743 [TBL] [Abstract][Full Text] [Related]
16. PYY3-36 as an anti-obesity drug target. Boggiano MM; Chandler PC; Oswald KD; Rodgers RJ; Blundell JE; Ishii Y; Beattie AH; Holch P; Allison DB; Schindler M; Arndt K; Rudolf K; Mark M; Schoelch C; Joost HG; Klaus S; Thöne-Reineke C; Benoit SC; Seeley RJ; Beck-Sickinger AG; Koglin N; Raun K; Madsen K; Wulff BS; Stidsen CE; Birringer M; Kreuzer OJ; Deng XY; Whitcomb DC; Halem H; Taylor J; Dong J; Datta R; Culler M; Ortmann S; Castañeda TR; Tschöp M Obes Rev; 2005 Nov; 6(4):307-22. PubMed ID: 16246216 [TBL] [Abstract][Full Text] [Related]
17. Increased brain neuropeptide Y1 and Y2 receptor binding in NPY knock out mice does not result in increased receptor function. Gehlert DR; Shaw JL Peptides; 2007 Feb; 28(2):241-9. PubMed ID: 17208335 [TBL] [Abstract][Full Text] [Related]
18. Intravenous peptide YY3-36 and Y2 receptor antagonism in the rat: effects on feeding behaviour. Scott V; Kimura N; Stark JA; Luckman SM J Neuroendocrinol; 2005 Jul; 17(7):452-7. PubMed ID: 15946163 [TBL] [Abstract][Full Text] [Related]
19. Indolyl and dihydroindolyl N-glycinamides as potent and in vivo active NPY5 antagonists. Wu L; Lu K; Packiarajan M; Jubian V; Chandrasena G; Wolinsky TC; Walker MW Bioorg Med Chem Lett; 2012 Mar; 22(6):2167-71. PubMed ID: 22361135 [TBL] [Abstract][Full Text] [Related]
20. Co-expression of neuropeptide Y Y1 and Y5 receptors results in heterodimerization and altered functional properties. Gehlert DR; Schober DA; Morin M; Berglund MM Biochem Pharmacol; 2007 Dec; 74(11):1652-64. PubMed ID: 17897631 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]